Leveraging the unique benefits of integrated CDMOs
RICK L. KNIGHT
Global Head Strategic Account Management, Pfizer CentreOne, Michigan, United States
Abstract
In the dynamic landscape of pharmaceutical outsourcing, Rick L. Knight, Global Head, Strategic Account Management at Pfizer CentreOne, reveals how biotech and pharma companies are increasingly turning to contract development and manufacturing organizations (CDMOs) for support in overcoming capacity constraints, accessing specialized expertise and accelerating time-to-market. He explores how integrated CDMOs (those embedded within leading pharmaceutical companies) offer distinct advantages, including established supplier relationships, access to cutting-edge facilities and deep regulatory knowledge to help bring therapies to patients sooner.
The journey to market for innovative therapies is fraught with difficulties. To deliver critical therapies to patients in need, biotech and pharmaceutical companies often face challenges as they transition their products from early-stage development to commercialization. Major hurdles include the need for extensive research and development, substantial financial investments, rigorous regulatory approvals and the development of robust manufacturing capabilities.
Increasingly, drug developers are seeking the support of contract development and manufacturing organizations (CDMOs), including “integrated” CDMOs. By leveraging their advanced manufacturing capabilities and scientific expertise, integrated CDMOs within leading pharmaceutical companies are helping their customers streamline drug development, mitigate risks and accelerate time-to-market for innovative therapies.
In this article, Rick L. Knight, Global Head, Strategic Account Management at Pfizer CentreOne, explores the challenges faced by the pharmaceutical industry in an ever-changing landscape and outlines why CDMOs are an increasingly strategic option overall. ...
